Ascendis Pharma A/S (ASND) News Today $170.79 +4.21 (+2.53%) As of 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Ascendis Pharma A/S (ASND) Expected to Announce Quarterly Earnings on ThursdayApril 30 at 3:20 AM | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Shares Bought by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 7.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,283,207 shares of the biotechnologyApril 28 at 5:08 AM | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Trading 4.4% Higher - Still a Buy?Ascendis Pharma A/S (NASDAQ:ASND) Trading 4.4% Higher - Time to Buy?April 27 at 11:37 AM | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Legal & General Group PlcLegal & General Group Plc increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1,577.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,682 shares of the biotechnology company's stApril 27 at 3:45 AM | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by T. Rowe Price Investment Management Inc.T. Rowe Price Investment Management Inc. increased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 54.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,725,546 shares ofApril 26, 2025 | marketbeat.comAscendis Pharma A/S (ASND) to Release Earnings on ThursdayAscendis Pharma A/S (NASDAQ:ASND) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-ascendis-pharma-as-stock/)April 26, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Guggenheim Capital LLCGuggenheim Capital LLC raised its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 256.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,249 shares of the biotechnology company's stock after purchasing an additional 5,218 shares during tApril 25, 2025 | marketbeat.comAscendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025April 24, 2025 | globenewswire.comAscendis Pharma A/S (NASDAQ:ASND) Stock Price Down 3.3% - Should You Sell?Ascendis Pharma A/S (NASDAQ:ASND) Shares Down 3.3% - Should You Sell?April 24, 2025 | marketbeat.comSilverarc Capital Management LLC Grows Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Silverarc Capital Management LLC raised its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 929.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 51,491 shares of the biotechnology company's stock after purchasing aApril 24, 2025 | marketbeat.comDiadema Partners LP Invests $3.48 Million in Ascendis Pharma A/S (NASDAQ:ASND)Diadema Partners LP acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,276 shares of the biotecApril 24, 2025 | marketbeat.comAvoro Capital Advisors LLC Has $702.54 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)Avoro Capital Advisors LLC boosted its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,103,055 shares of the biotechnology company's stoApril 23, 2025 | marketbeat.comRock Springs Capital Management LP Sells 20,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Rock Springs Capital Management LP trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 305,000 shares ofApril 23, 2025 | marketbeat.comCapital International Inc. CA Takes $1.15 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)Capital International Inc. CA purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,375 shares of the bApril 23, 2025 | marketbeat.comMarshall Wace LLP Sells 106,830 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Marshall Wace LLP cut its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 48.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 114,245 shares of the biotechnology company's stockApril 23, 2025 | marketbeat.comJump Financial LLC Invests $1.67 Million in Ascendis Pharma A/S (NASDAQ:ASND)Jump Financial LLC acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,105 shares of the biotechnology company's stock, valued aApril 22, 2025 | marketbeat.comCapital International Ltd. CA Invests $2.64 Million in Ascendis Pharma A/S (NASDAQ:ASND)Capital International Ltd. CA acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund acquired 19,153 shares of the biotechnology company's stock, valued at approximately $2,637,000. OtheApril 21, 2025 | marketbeat.comCapital International Investors Buys 753,859 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Capital International Investors raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 35.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,863,249 shares of the biotechnology company's stock after buyingApril 21, 2025 | marketbeat.comCapital International Sarl Invests $3.28 Million in Ascendis Pharma A/S (NASDAQ:ASND)Capital International Sarl purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 23,806 shares of the biotechnology companApril 21, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fifteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and fourteen haApril 21, 2025 | marketbeat.com3,609 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Bought by Capital Group Investment Management PTE. LTD.Capital Group Investment Management PTE. LTD. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,609 shares of the biApril 20, 2025 | marketbeat.comRoyal Bank of Canada Initiates Coverage on Ascendis Pharma A/S (NASDAQ:ASND)Royal Bank of Canada assumed coverage on Ascendis Pharma A/S in a research note on Wednesday. They issued an "outperform" rating and a $205.00 target price on the stock.April 18, 2025 | marketbeat.comAscendis Pharma (ASND) Gets a Buy from Bank of America SecuritiesApril 17, 2025 | markets.businessinsider.comAscendis Pharma (ASND) Has a New Rating from RBC CapitalApril 17, 2025 | markets.businessinsider.comRBC Capital Initiates Coverage of Ascendis Pharma A (ASND) with Outperform RecommendationApril 17, 2025 | msn.comJPMorgan Chase & Co. Buys 37,593 Shares of Ascendis Pharma A/S (NASDAQ:ASND)JPMorgan Chase & Co. increased its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 94.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 77,427 shares of the biotechnology company's stock after purchasing an addiApril 16, 2025 | marketbeat.comInvesco Ltd. Trims Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Invesco Ltd. lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,156,013 shares of the biotechnology company's stock after selling 6,April 15, 2025 | marketbeat.comAscendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch TrajectoryApril 14, 2025 | seekingalpha.comIs Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?April 14, 2025 | insidermonkey.comAscendis Pharma (ASND) Receives a Buy from Evercore ISIApril 14, 2025 | markets.businessinsider.comEvolutionary Tree Capital Management LLC Has $4.15 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Evolutionary Tree Capital Management LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 8.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,115 shares of the biotechnology company's stock after selliApril 14, 2025 | marketbeat.comSterling Capital Management LLC Purchases 9,065 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Sterling Capital Management LLC grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 19.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,850 shares of the biotechnoloApril 14, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Purchased by FIL LtdFIL Ltd lifted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 13.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 729,275 shares of the biotechnology company's stock after purchasing aApril 12, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Down 7.4% - Should You Sell?Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Down 7.4% - What's Next?April 11, 2025 | marketbeat.comFmr LLC Sells 179,199 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Fmr LLC trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,728,647 shares of the biotechnology company's stock after selling 17April 11, 2025 | marketbeat.comADAR1 Capital Management LLC Has $9.83 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)ADAR1 Capital Management LLC lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 55.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 71,402 shares of the biotechnology company's stock after selling 90,April 9, 2025 | marketbeat.comFinepoint Capital LP Reduces Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)Finepoint Capital LP trimmed its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.7% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 184,872 shares of the biotechnology company's stock after selling 5,200 sharApril 8, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Bought by Trexquant Investment LPTrexquant Investment LP lifted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 235.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,067 shares of the biotechnology compaApril 8, 2025 | marketbeat.comAlliancebernstein L.P. Sells 9,760 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Alliancebernstein L.P. trimmed its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 445,028 shares of the biotechnology company's stock after selling 9,760April 7, 2025 | marketbeat.comWellington Management Group LLP Lowers Position in Ascendis Pharma A/S (NASDAQ:ASND)Wellington Management Group LLP trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 44.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 704,175 shares of thApril 5, 2025 | marketbeat.comSchroder Investment Management Group Purchases 11,739 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Schroder Investment Management Group increased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 14.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,728 shares of the biotechnology company's stock after buying an additionalApril 5, 2025 | marketbeat.comNomura Asset Management Co. Ltd. Purchases 2,506 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Nomura Asset Management Co. Ltd. boosted its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,506 shares of the biotechApril 4, 2025 | marketbeat.comNew Age Alpha Advisors LLC Invests $507,000 in Ascendis Pharma A/S (NASDAQ:ASND)New Age Alpha Advisors LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 3,680 shares of the biotechnology company's stock, valued at approximately $507,000.April 3, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Groupama Asset ManagmentGroupama Asset Managment trimmed its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 400,000 shares of the biotechnology company's stock after selling 4,000 shares duriApril 2, 2025 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Shares Sold by Pictet Asset Management Holding SAPictet Asset Management Holding SA reduced its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 144,199 shares of the biotechnology company's stock afterApril 2, 2025 | marketbeat.comAscendis Pharma submits TransCon CNP NDA to FDAApril 1, 2025 | markets.businessinsider.comAscendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with AchondroplasiaMarch 31, 2025 | globenewswire.comHighTower Advisors LLC Takes $484,000 Position in Ascendis Pharma A/S (NASDAQ:ASND)HighTower Advisors LLC acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,514 shares of the biotechnology company's stock, valued at approximately $484,00March 31, 2025 | marketbeat.comLoomis Sayles & Co. L P Sells 5,724 Shares of Ascendis Pharma A/S (NASDAQ:ASND)Loomis Sayles & Co. L P cut its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 178,899 shares of the biotechnology company's stock after selling 5,724 shares duriMarch 30, 2025 | marketbeat.comNEOS Investment Management LLC Has $2.62 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)NEOS Investment Management LLC raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 43.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,040 shares of the biotechnology company'sMarch 30, 2025 | marketbeat.com Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Media Mentions By Week ASND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼1.260.85▲Average Medical News Sentiment ASND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼127▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARGX News Today BNTX News Today ONC News Today SMMT News Today TEVA News Today ITCI News Today GMAB News Today RDY News Today MRNA News Today VTRS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredYou’re About to Lose Everything – Act Now or Regret It ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASND Stock Free ASND Stock Alerts